BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer: An immunohistochemical study

Applied Immunohistochemistry

Volumn 8, Issue 1, 2000, Pages 12-18

  Özer, Erdener ^a   Sis, Banu ^a   Özen, Emek ^a   Sakizli, Meral ^a   Canda, Tülay ^a   Sarioǧlu, Sülen ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

BRCA1; Breast cancer; C erbB 2; H ras; Young women

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; ONCOGENE C ERB; ONCOGENE H RAS; PRIORITY JOURNAL;

ADULT; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, BRCA1; GENES, ERBB-2; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RAS PROTEINS; RECEPTOR, ERBB-2;

EID: 1642618135     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200003000-00002     Document Type: Article

References (27)

1. Xing WR, Gilchrist KW, Harris CP, Samson W, Meisner LF. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 1996;39:203-12.
2. Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997;28:1180-8.
3. Somasundaram K, Zhang H, Zeng YX, Hauvras Y, Peng Y, Zhang H, Wu GS, Weber BL, El-Deiry WS. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/ CiP1. Nature 1997;389:187-90.
4. Connon-Albright LA, Skolnick MH. The genetics of familial breast cancer. Semin Oncol 1996;23:1-5.
5. Jarvis EM, Kirk JA, Clarke CL. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 1998;10:109-15.
6. Waldman V, Robes HM. What's new in ras genes? Physiological role of ras genes in signal transduction and significance of ras gene activation in tumorigenesis. Pathol Res Pract 1996;192:883-91.
7. Janacco LE, Lucke JF, Growth DW, Brown KA, Smith CA, Pollice AA, Singh SG, Yakulis R, Hartsock RJ, Shackney SE Assessing sequential oncogene amplification in human breast cancer. Cytometry 1995;21:18-22.
8. Anderson BO, Senie RT, Vetto JT, Wong GY, McCormick B, Borgen BI. Improved survival in young women with breast cancer. Ann Surg Oncol 1995;2:407-15.
9. Sariego J, Zrada S, Byrd M, Matsumo T. Breast cancer in young patients. Am J Surg 1995;170:243-5.
10. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer-histopathological and prognostic considerations. Br J Cancer 1997;75:1318-23.
11. Fisher B, Bauer M, Wickerman L, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Mangoloso B. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52: 1555-7.
12. De Vita VT Jr, Hellman S, Rosenberg SA. Cancer, principles and practice of oncology. Philadelphia: JB Lippincott, 1985.
13. Elston JW, Ellis IO. Pathological prognostic factors in breast cancer: experience from a large study with long-term:follow-up. Histopathology 1991;19:403-10.
14. Ozer E, Canda T, Kuyucuoglu F. p53 mutations in bilateral breast carcinoma. Correlation with Ki-67 expression and the mean nuclear volume. Cancer Lett 1998;22:101-6.
15. de Manzoni G, Verlato G, Tomezzoli A, Guglielmi A, Pelosi G, Ricci F, DiLeo A, Cordiano C. Study on Ki-67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol 1998;28:534-7.
16. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connely JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR. Relationship of patients age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994;12:888-94.
17. Bertheu P, Steinberg SM, Merino MJ. c-er6B-2, p53, and nm23 gene product expression in breast cancer in young women: immnohistochemical analysis and clinicopathologic correlation. Hum Pathol 1998;29:323-9.
18. Dawkins HJ, Robbins PD, Smith KL, Sarna M, Harvey JM, Sterret GF, Papadimitrio JM. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. Pathol Res Pract 1993;189: 1233-52.
19. Quenel N, Wafflat J, Bonichon F, de Mascarel I, Trojoni M, Durand M, Avril A, Coindre JM. The prognostic value of c-erbB-2 in primary breast carcinomas: a case study on 942 cases. Breast Cancer Res Treat 1995;35:283-91.
20. Rosen PP, Lesser ML, Arroya CD, Cranor M, Bergen P, Norton L. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features and prognosis. Cancer 1995; 75:1320-6.
21. McKenna WG, Weiss MC, Bakanauskas VJ, Sandler H, Kelsten ML, Biaglow J, Tutle SW, Endlich B, Ling CC, Muschel RJ. The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 1990;18:849-59.
22. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher UM, McCormick JJ, Klebe RJ. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998;16:483-96.
23. Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, Conti CJ, Jarcono JL. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 1996;6:5395-6.
24. Watson DM, Elton RA, Jack WJ, Dixon JM, Chetty U, Miller WR. The H-ras oncogene product p21 and prognosis in breast cancer. Breast Cancer Res Treat 1991;17:161-9.
25. Jin Y, Xu XL, Yang MC, Wei F, Ayi TC, Bowcock AM, Baer R. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc Natl Acad Sci USA 1997; 94:12075-80.
26. Langsten AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based young women with breast cancer. N Engl J Med 1996;18:137-42.
27. Couch FJ, Weber BL. Mutations and polymorphism in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat 1996;8:8-18.